Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.84 |
| ▸ | HPGD | P15428 | 1/20 | 0.84 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | XDH | P47989 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25933542 | 0.93 | ALDH1A1 (0.92) | ALDH1A1HPGD | |
| SCHEMBL12432349 | 0.92 | ALDH1A1 (1.00) | ALDH1A1HPGD | |
| SCHEMBL8943492 | 0.92 | ALDH1A1 (1.00) | ALDH1A1HPGD | |
| SCHEMBL16188294 | 0.88 | ALDH1A1 (0.67) | ALDH1A1HPGDXDH | |
| SCHEMBL1402221 | 0.88 | ALDH1A1 (0.74) | ALDH1A1HPGDXDH | |
| SCHEMBL2590779 | 0.87 | ALDH1A1 (0.73) | ALDH1A1HPGDXDH | |
| SCHEMBL30629073 | 0.87 | ALDH1A1 (0.73) | ALDH1A1HPGDXDH | |
| SCHEMBL25315406 | 0.87 | ALDH1A1 (0.72) | ALDH1A1HPGDXDH | |
| SCHEMBL4720152 | 0.86 | ALDH1A1 (0.64) | ALDH1A1HPGDXDH | |
| Biphenyl SCHEMBL11433077 | 0.86 | ALDH1A1 (0.88) | ALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3630738-A1 | PROCESS FOR THE PRODUCTION OF OZANIMOD | Egis Gyógyszergyár Zrt. (HU) | 2020-04-08 | — | — | EP | claimed |
| WO-2018215807-A1 | PROCESS FOR THE PRODUCTION OF OZANIMOD | EGIS GYÓGYSZERGYÁR ZRT. (HU) | 2018-11-29 | — | — | WO | claimed |
| CN-110997645-A | Preparation method of ozanimod | 埃吉斯制药公司 | 2020-04-10 | — | — | CN | disclosed |
| EP-3630738-A1 | PROCESS FOR THE PRODUCTION OF OZANIMOD | Egis Gyógyszergyár Zrt. (HU) | 2020-04-08 | — | — | EP | disclosed |
| WO-2018215807-A1 | PROCESS FOR THE PRODUCTION OF OZANIMOD | EGIS GYÓGYSZERGYÁR ZRT. (HU) | 2018-11-29 | — | — | WO | disclosed |
| US-9707205-B2 | S1P receptors modulators and their use thereof | AKAAL PHARMA PTY LTD. (AU) | 2017-07-18 | — | — | US | disclosed |
| EP-2595989-B1 | HETEROCYCLIC CHROMENE-SPIROCYCLIC PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS | VERTEX PHARMA (US) | 2016-07-13 | — | — | EP | disclosed |
| EP-2383262-B1 | PHENYL PYRIMIDONE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, PREPARATION METHODS AND USES THEREOF | TOPHARMAN SHANGHAI CO LTD (CN) | 2016-07-06 | — | — | EP | disclosed |
| US-9365588-B2 | Benzoxazines as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2016-06-14 | — | — | US | disclosed |
| EP-2344484-B1 | S1P RECEPTORS MODULATORS AND USE THEREOF | AKAAL PHARMA PTY LTD (AU) | 2016-06-08 | — | — | EP | disclosed |
| US-20160038455-A1 | S1P RECEPTORS MODULATORS AND THEIR USE THEREOF | AKAAL PHARMA PTY LTD. (AU) | 2016-02-11 | — | — | US | disclosed |
| US-7618981-B2 | to treat cellular proliferative diseases, hyperplasias, solid tumor, cardiac hypertrophy, immune disorders and inflammation; modulators of one or more mitotic kinesins; N-(2-(2-dimethylamino-acetylamino)-1-{4-[8-(1-hydroxy-ethyl)-imidazo[1,2-a]pyridin-2-yl]-benzyl}-ethyl)-3-chloro-4-isopropoxy-benzamide | CYTOKINETICS, INC. (US) | 2009-11-17 | — | — | US | disclosed |
| EP-1951719-A2 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | Cytokinetics, Inc. (US) | 2008-08-06 | — | — | EP | disclosed |
| EP-1942899-A2 | MITOTIC KINESIN INHIBITORS | Cytokinetics, Inc. (US) | 2008-07-16 | — | — | EP | disclosed |
| EP-1742907-A4 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | CYTOKINETICS INC (US) | 2008-01-02 | — | — | EP | disclosed |
| US-20070219192-A1 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INCORPORATED | 2007-09-20 | — | — | US | disclosed |
| WO-2007056056-A2 | MITOTIC KINESIN INHIBITORS | CYTOKINETICS, INC. (US) | 2007-05-18 | — | — | WO | disclosed |
| WO-2007056469-A2 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | CYTOKINETICS, INC. (US) | 2007-05-18 | — | — | WO | disclosed |
| EP-1742907-A2 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | Cytokinetics, Inc. (US) | 2007-01-17 | — | — | EP | disclosed |
| WO-2005107762-A2 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | CYTOKINETICS, INC. (US) | 2005-11-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160038455-A1 | S1P RECEPTORS MODULATORS AND THEIR USE THEREOF | S1PR1, S1PR5, S1PR2 | ALDH1A1 3172/4885HPGD 2567/4885KMT2A 2386/4885 |
| US-20070219192-A1 | Certain chemical entities, compositions, and methods | KIF5B, KIF2C, PLK1 | ALDH1A1 2159/4885HPGD 2681/4885KMT2A 1501/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.